SELESTIAL: Trial of Insulin to Control Blood Sugar After Acute Stroke Using Magnetic Resonance Imaging (MRI) End-Points

January 31, 2006 updated by: University of Glasgow

Spectroscopic Evaluation of Lesion Evolution in Stroke: Trial of Insulin for Acute Lactic Acidosis (SELESTIAL)

High blood sugar (hyperglycaemia) affects 40% of acute stroke patients and has a major adverse effect on survival and recovery. Increased production of lactic acid in brain tissue that has a poor blood supply is postulated to be the mechanism by which high blood sugar may worsen brain injury after stroke. Treatment with insulin infusions is proposed as a neuroprotective strategy, and a clinical trial is ongoing to test this hypothesis. However, the biological basis for insulin treatment has not been established, and there is uncertainty about the duration of insulin infusion that may be required to limit damage.

Magnetic resonance spectroscopy (MRS) is a brain scanning technique that allows measurement of brain lactic acid. When performed in conjunction with conventional MRI scanning, the relationship of lactate accumulation to stroke expansion can be established. SELESTIAL is a randomised, placebo-controlled trial of insulin infusions of 24 or 72 hours (h) duration in acute stroke patients with hyperglycaemia, to establish whether insulin prevents lactate accumulation over the initial 72h after stroke, how this relates to stroke evolution, and the effect of treatment on stroke size and clinical outcomes at 1 week.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Hyperglycaemia is present in 40-60% of patients with acute ischaemic stroke and adversely affects survival and outcome. This effect is independent of stroke severity or pathology, and is most striking in patients without recognised diabetes, in whom the odds of death are increased threefold, and the chance of poor functional outcome by 40%. Hyperglycaemia remains a powerful independent predictor of outcome even in the face of thrombolytic drug therapy.

The adverse effect of hyperglycaemia is hypothesised to be consequent to increased provision of substrate to hypoperfused tissue that is metabolising anaerobically, with resultant tissue accumulation of neurotoxic lactic acid. In animal models of stroke, hyperglycaemia causes increased tissue lactic acidosis and increased recruitment of ischaemic tissue in the peri-infarct region into the final infarct. Infarct volumes are higher in hyperglycaemic animals, and conversely, reducing blood glucose reduces infarct volume. Although clinical observational studies suggest protocols that incorporate blood glucose monitoring and control to be beneficial, and trials are ongoing to define the impact of routine treatment to maintain euglycaemia, the basic pathophysiology of stroke in relation to blood glucose has not been well defined in man. Preliminary studies confirm a relationship between blood glucose and lactate concentration in hypoperfused brain tissue but it is unknown whether brain lactate is reduced by control of blood glucose, and whether doing so will impact on stroke evolution. It has also been found that infarct volume increases more in hyperglycaemic patients treated with recombinant tissue plasminogen activator (rtPA).

MRI permits non-invasive and serial study of acute stroke pathophysiology. In addition to brain structure, MRI can define tissue viability (cytotoxic oedema seen on diffusion-weighted imaging, DWI), brain perfusion (bolus-tracking perfusion imaging, PI), vascular integrity (MR angiography, MRA) and tissue metabolism (1H MR spectroscopy, MRS). In acute middle cerebral artery (MCA) occlusion, evolution of cerebral damage has been defined with these techniques. The volume of hypoperfused tissue on PI initially exceeds the DWI lesion, and, over time, the DWI lesion expands to finally incorporate the majority of the PI lesion. The region of tissue with normal DWI but abnormal PI is thought to correspond to the "ischaemic penumbra", the region where hypoperfusion causes electrical failure of neurones with progression to infarction over time due to adverse metabolic and neurochemical events. The fate of the penumbra may be determined by treatment - e.g. it is salvaged by thrombolysis - and it is this penumbral region that is vulnerable to hyperglycaemia-related lactic acidosis.

Glucose lowering with insulin is an inexpensive, and widely applicable treatment. However, current clinical trials are compromised by uncertainty over the ability of treatment to influence pathophysiology, and have necessarily relied upon a "best guess" for treatment duration. Definition of the biological basis for insulin treatment by MRI criteria and comparative data for different treatment durations would strengthen and inform any positive effect from clinical trials, or prevent premature abandonment of this therapeutic modality should trials be neutral.

Study Type

Interventional

Enrollment

45

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Glasgow, United Kingdom, G51 4TF
        • Institute of Neurological Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Acute stroke within 24h of onset
  • Lesion on acute diffusion weighted MRI
  • >18 years age

Exclusion Criteria:

  • Coma
  • Major concomitant illness limiting survival

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Lesion volume expansion at 1 week

Secondary Outcome Measures

Outcome Measure
Brain lactate concentration change baseline-day 3
Change in National Institutes of Health Stroke Scale (NIHSS) baseline - day 7
30 day modified Rankin Scale score
30 day NIHSS
30 day Barthel Index

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Glasgow

Collaborators

South Glasgow University Hospitals NHS Trust
The Stroke Association, United Kingdom

Investigators

  • Principal Investigator: Keith Muir, MD, University of Glasgow

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2004

Study Registration Dates

First Submitted

July 26, 2005

First Submitted That Met QC Criteria

July 27, 2005

First Posted (Estimate)

July 28, 2005

Study Record Updates

Last Update Posted (Estimate)

February 1, 2006

Last Update Submitted That Met QC Criteria

January 31, 2006

Last Verified

July 1, 2005

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 04/S0702/58
  • Grant No: TSA 06/03
  • MREC Ref: 04/MRE00/31
  • R&D Ref: R030295

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperglycemia

Clinical Trials on Insulin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe